Hartland, 

Patients in both groups are going to have MACE events. I guess I should have clarified that with a modest relative risk reduction, the stats might not be strong enough yet to conclude statistical efficacy. At some unknown/arbitrary %RRR, the data is less black and white and turns to shades of gray. But in your hypothetical scenario of 66.6 events in the placebo group and 33.3 events in the apabetalone group (50% RRR) then most likely that would be significant! Those might be the kind of numbers to recommend early termination! Just my opinion of course. 

BearDownAZ